title: Inflammatory biomarkers and statins.
abstract: The concept of atherosclerosis as an inflammatory disorder has led to the exploration of new pathogeneses of this disease. In this regard, the levels of several inflammatory molecules are frequently increased in subjects at high risk of developing an acute coronary event. With a simple analysis we can characterize the circulating levels of a marker and its therapeutic modulation with various drugs. In this review we have analyzed different inflammatory markers currently used, such as C-reactive protein (CRP), CD40 ligand, adhesion molecules and chemokines, and their possible modulation by therapeutic intervention with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Moreover, in the future, new technologies will allow us to discover new markers, or sets of them, that could indicate the direction to be taken in the prevention and treatment of cardiovascular diseases.
authors.affiliation: Vascular Research Lab, Department of Cardiology, Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
authors.forename: Luis Miguel
authors.initials: LM
authors.lastname: Blanco-Colio
authors.forename: José
authors.initials: J
authors.lastname: Tuñón
authors.forename: José Luis
authors.initials: JL
authors.lastname: Martín-Ventura
authors.forename: Jesús
authors.initials: J
authors.lastname: Egido
mesh_terms: D050197:Atherosclerosis / Q000097:blood / Q000175:diagnosis; D015415:Biomarkers / Q000097:blood*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood; D011237:Predictive Value of Tests; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors